Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516162 | 1.00 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7669406 | 1.00 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7291113 | 0.92 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7291105 | 0.92 | SLC6A3 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9405548 | 0.90 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9405547 | 0.90 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL9405598 | 0.90 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6792848 | 0.89 | SLC6A3 (0.72) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7288922 | 0.89 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7288917 | 0.89 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660863-B2 | Reacting an cycloheptatriene nitrile compound with nortropane compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| US-6596868-B2 | Reacting a cycloheptatriene derivative with a primary amine or ammonia in the presence of a base | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-06-12 | — | — | US | disclosed |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-09-06 | — | — | US | disclosed |
| EP-1127887-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | SLC6A3 385/4885SLC6A2 185/4885SLC6A4 908/4885 |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | SLC6A3 385/4885SLC6A2 185/4885SLC6A4 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.